Oncology is an area of serious unmet needs presenting overwhelming opportunities for antibody-drug conjugates (ADCs) directed to various cancers. Meditope Biosciences' SnAP technology is uniquely suited to take advantage of those opportunities and revolutionize the way ADCs are created.
Now that we've completed informative research to validate the use of SnAP technology, we are transitioning into early drug discovery and have established our own research and development capabilities to build a pipeline of antibody-drug conjugates (ADCs) candidates.
By expanding antibody functionality, SnAP technology can expedite and optimize the oncology drug development process. We have identified and narrowed our focus to a handful of oncology targets to which antibodies already exist. By creating a 'palette' of meditope-enabled versions of these antibodies and another 'palette' of meditope-linker pieces conjugated to various payloads, we can mix and match our pieces and ultimately identify the lead ADC candidate for moving towards the clinic.